<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Dementia. Diagnosis and treatment.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Regional Health Council. Dementia. Diagnosis and treatment. Milan (Italy): Regione Toscana, Consiglio Sanitario Regionale; 2011. 38 p.  [131 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="HCPCS: Mental health services, not otherwise specified "/><FieldValue Value="ICD9CM: Behavior therapy  (94.33); Major depressive affective disorder, recurrent episode, unspecified  (296.30); Major depressive affective disorder, single episode, unspecified  (296.20); Occupational therapy  (93.83)"/><FieldValue Value="MSH: Antidepressive Agents ; Antipsychotic Agents ; Behavior Therapy ; Benzodiazepines ; Blood Chemical Analysis ; Cholinesterase Inhibitors ; Cognitive Therapy ; Comorbidity ; Delirium ; Dementia ; Depression ; Depressive Disorder ; Diagnosis, Differential ; Diagnostic Imaging ; Geriatric Assessment ; Hematologic Tests ; Interview, Psychological ; Magnetic Resonance Imaging ; Memantine ; Mental Health Services ; Occupational Therapy ; Psychological Techniques ; Referral and Consultation ; Risk Assessment ; Risk Factors ; Tomography Scanners, X-Ray Computed ; Tomography, X-Ray Computed "/><FieldValue Value="MTH: Acetylcholinesterase Inhibitors ; Antidepressive Agents ; Benzodiazepines ; Blood Chemical Analysis ; Cholinesterase Inhibitors ; Clinical dementia rating scale ; Cognitive Therapy ; Computed Tomography Scanning Systems ; Delirium ; Dementia ; Dementia, Senile ; Depressive Disorder ; Diagnostic Imaging ; Differential Diagnosis ; Geriatric depression scale (assessment scale) ; Hematologic Tests ; Imaging of brain ; Magnetic Resonance Imaging ; Mental Depression ; Occupational therapy regime ; Risk Assessment ; risk factors ; X-Ray Computed Tomography "/><FieldValue Value="PDQ: computed tomography ; delirium ; diagnostic imaging ; magnetic resonance imaging "/><FieldValue Value="SNOMEDCT_US: Anti-psychotic agent  (10784006); Anti-psychotic agent  (372482001); Anticholinesterase drug  (372765004); Anticholinesterase drug  (52761007); Antidepressant  (36236003); Antidepressant  (372720008); Behavioral therapy  (166001); Benzodiazepine  (16047007); Benzodiazepine  (372664007); Blood chemistry  (166312007); Blood test  (252275004); Blood test  (396550006); Clinical dementia rating scale  (273367002); Cognitive therapy  (183383008); Cognitive therapy  (228553007); Cognitive therapy  (228557008); Cognitive therapy  (304891004); Computerized axial tomography  (77477000); Delirium  (2776000); Delirium  (419567006); Dementia  (52448006); Depressive disorder  (21061000119107); Depressive disorder  (35489007); Differential diagnosis  (47965005); Geriatric depression scale  (273481004); Geriatric screening  (171313004); Imaging  (363679005); Imaging of brain  (441986001); Initial psychiatric assessment  (170679009); Magnetic resonance imaging  (113091000); Magnetic resonance imaging  (312250003); Magnetic resonance imaging unit  (90003000); Memantine  (406457005); Memantine  (406458000); Mental health service  (708168004); Occupational therapy  (84478008); Psychiatric interview and evaluation  (10197000); Reality orientation  (228547007); Recurrent major depressive episodes  (268621008); Recurrent major depressive episodes  (66344007); Risk assessment  (225338004); Risk factor  (80943009); Senile dementia  (15662003); Single major depressive episode  (268620009); Single major depressive episode  (36923009)"/><FieldValue Value="SPN: SYSTEM, NUCLEAR MAGNETIC RESONANCE IMAGING ; SYSTEM, X-RAY, TOMOGRAPHY, COMPUTED "/><FieldValue Value="UMD: Scanning Systems, Computed Tomography  (13-469); Scanning Systems, Magnetic Resonance Imaging  (16-260)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Dementia&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Diagnosis" /><FieldValue Value="Management" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Family Practice" /><FieldValue Value="Geriatrics" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Neurology" /><FieldValue Value="Psychiatry" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Nurses" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /><FieldValue Value="Psychologists/Non-physician Behavioral Health Clinicians" /><FieldValue Value="Social Workers" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To summarize the most reliable indications from scientific literature on assessment tests and pharmacological and non-pharmacological treatments of dementia, to benefit of general practitioners and health professionals involved in the diagnostic-therapeutic process&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Patients with suspected or confirmed dementia&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Diagnosis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Assessment of clinical signs of dementia &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assessment of symptoms of depression using Geriatric Depression Scale &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assessment of delirium using diagnostic criteria &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assessment of dementia using diagnostic criteria &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Use of anamnesis, general examination, assessment of possible iatrogenic causes, and structured interview &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assessment of pathological conditions &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assessment for presence of co-morbidities and risk factors &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Blood tests &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Brain imaging (computed tomography [CT], magnetic resonance [MR]) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Referral to specialist, if indicated &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Treatment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Pharmacological treatments&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Treatment of core symptoms with acetylcholinesterase inhibitors and memantine &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Treatment of associated symptoms with antidepressants or antipsychotics &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Non-pharmacological treatments, including cognitive behavioral therapy (CBT), occupational therapy, and Reality Orientation Therapy (ROT) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: Mood stabilizers and benzodiazepines were considered but not recommended for the treatment of associated symptoms.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Accuracy and utility of diagnostic tests in differential diagnosis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Effectiveness of pharmacological and non-pharmacological treatment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adverse effects of pharmacological treatment &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following databases were searched: PubMed, the Cochrane Database of Systematic Reviews, the Cochrane Central Register of Controlled Trials, the Database of Abstracts of Reviews of Effects, Trip Database, Clinical Evidence, and the National Guideline Clearinghouse. The time frame was limited to the last decade, and the search was limited to systematic reviews and randomized controlled trials. Search terms were &quot;dementia and primary and care,&quot; &quot;dementia and diagnosis,&quot; &quot;dementia and treatment or therapy,&quot; &quot;dementia and pharmacological and treatment,&quot; &quot;dementia and non-pharmacological and treatment,&quot; &quot;dementia and neuroleptics or antipsychotics.&quot;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In addition, the most recent and accredited guidelines, and all available consensus statements expressed by the main scientific societies specialized in neurological pathologies have been consulted:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Dementia Study Group of the Italian Neurological Society &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Scottish Intercollegiate Guidelines Network (SIGN) 86: Management of patients with dementia, February 2006 &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Royal College of Physicians &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Royal Australian College of General Practitioners &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;U.S. Preventive Services Task Force (USPSTF) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Work group on Guideline for Alzheimer's Disease Management, 2008 &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;European Federation of the Neurological Societies (EFNS) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;National Institute for Health and Clinical Excellence (NICE) Clinical Guidelines &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Dementia and Neurodegenerative Diseases Research Network (DeNDRoN) Primary Care Study Group &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Database of Abstracts of Reviews of Effects (DARE) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cochrane Database of Systematic Reviews &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;National Institute of Neurological Disorders and Stroke &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Level of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;I&lt;/strong&gt; Evidences from randomized controlled clinical trials and/or systematic reviews of randomized trials.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;II&lt;/strong&gt; Evidences from one single adequately designed randomized trial.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;III&lt;/strong&gt; Evidences from non-randomized cohort studies with concurrent or historical control or their metaanalysis.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;IV&lt;/strong&gt; Evidences from non-controlled retrospective case-control studies.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;V&lt;/strong&gt; Evidences from non-controlled case-series studies.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;VI&lt;/strong&gt; Evidences from experts' opinions or opinions from panels as indicated in guidelines or consensus conferences, or based on opinions from members of the work group responsible for this guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Comprehensive analysis of selected scientific literature by the panel of experts&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Strength of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt; Carrying out the specified procedure or diagnostic test is strongly recommended. The recommendation is supported by good-quality evidences, even if not necessarily type I or II.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; It would be inappropriate to always recommend the specified procedure or intervention, considered the still existing doubts, but it should anyway be carefully considered.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; Significant uncertainties exist against recommending to carry out the specified procedure or intervention.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; The specified procedure is not recommended.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;E&lt;/strong&gt; The specified procedure is strongly not recommended.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The guideline developer reviewed published cost analyses.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The grades of recommendations (A-E) and the levels of evidence (I-VI) are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;General Indications for Diagnosis&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;I/A&lt;/strong&gt; - The general practitioner knows the cognitive-behavioral profile of his/her patients and can identify the clinical signs of cognitive decay at their onset, taking also into account the observations of relatives.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;III/A&lt;/strong&gt; - The general practitioner should assess the presence of symptoms of depression in case of cognitive-behavioral alterations, adopting, if it is the case, psychometric tools and other professional competences. The use of the Geriatric Depression Scale with 15 items is suggested (see the original guideline document).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;III/A&lt;/strong&gt; - Delirium can be suspected in subjects presenting a clinical/behavioral profile similar to the one described by the &lt;em&gt;Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision&lt;/em&gt; (DSM-IV-TR) diagnostic criteria.&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; summary=&quot;Table: Diagnostic Criteria of Delirium Due to a General Medical Condition&quot; cellpadding=&quot;3&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;strong&gt;Diagnostic Criteria of Delirium Due to a General Medical Condition&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;            (From Diagnostic and Statistical Manual of Mental Disorders, IV Edition, Text Revision, 2000) &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Disturbance of consciousness (reduced clarity of awareness of the environment) with reduced ability to focus, sustain, or shift attention. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;A change in cognition (such as memory deficit, disorientation, language disturbance) or the development of a perceptual disturbance that is not better accounted for by a preexisting, established, or evolving dementia. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;The disturbance develops over a short period of time (usually hours to days) and tends to fluctuate during the course of the day. &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;There is evidence from the history, physical examination, or laboratory findings that the disturbance is caused by the direct physiological consequences of a general medical condition &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;I/A&lt;/strong&gt; - Dementia can be suspected in subjects presenting a clinical profile similar to the one described by the DSM-IV criteria for the definition of dementia.&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; summary=&quot;Table: Diagnostic Criteria for Dementia from the DSM-IV, 1994 (multiple etiologies)&quot; cellpadding=&quot;3&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Diagnostic Criteria for Dementia from the DSM-IV, 1994 (multiple etiologies)&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;A&lt;/strong&gt; The development of multiple cognitive deficits manifested by both&#xD;&#xA;            &lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Memory impairment (impaired ability to learn new information or to recall previously learned information) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;One (or more) of the following cognitive disturbances:&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;Aphasia (language disturbance) &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Apraxia (impaired ability to carry out motor activities despite intact motor function) &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Agnosia (failure to recognize or identify objects despite intact sensory function) &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Disturbance in executive functioning (planning, organizing, sequencing, abstracting) &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/li&gt;&#xD;&#xA;            &lt;/ol&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;B&lt;/strong&gt; The cognitive deficits in Criteria A1 and A2 each cause significant impairment in social or occupational functioning and represent a significant decline from a previous level of functioning.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;C&lt;/strong&gt; The deficits do not occur exclusively during the course of a delirium.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;I/A&lt;/strong&gt; - The general practitioner raises the diagnostic hypothesis of dementia through the anamnesis, a general examination, an assessment of possible iatrogenic causes, and a structured interview, carried out within a multi-professional team.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;VI/A&lt;/strong&gt; - General practitioners should assess all pathological conditions that could cause cognitive disorders.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;VI/A&lt;/strong&gt; - In raising the diagnostic hypothesis of dementia, general practitioners should assess the presence of co-morbidities and identify risk factors due to social isolation.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;VI/B&lt;/strong&gt; - General practitioners should prescribe blood tests to patients with suspect dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;VI/A&lt;/strong&gt; - General practitioners should prescribe to patients with suspect dementia a brain imaging exam (computed tomography [CT] or magnetic resonance [MR]) for a diagnostic definition of dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;VI/A&lt;/strong&gt; - General practitioners can refer to specialist services for diagnostic confirmation, differential diagnosis, and for the organization of interventions and stabilization of complex situations.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Treatment&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Pharmacological Treatment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Core Symptoms&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Acetylcholinesterase Inhibitors&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;I/A&lt;/strong&gt; - Starting a therapy with acetylcholinesterase inhibitors, whose effectiveness on core symptoms is proven, should be considered at moment of diagnosis of mild and moderate Alzheimer's disease. Expected benefits and potential adverse effects of the treatment should be discussed with patients and caregivers. Evidence of effectiveness of acetylcholinesterase inhibitors is available also in dementia with Lewy bodies and in dementia associated with Parkinson's disease. The option of starting a therapy with memantine should be considered in patients with moderate-severe Alzheimer's disease to treat core symptoms. No evidence is available on natural remedies.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Associated Symptoms&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Antidepressant Drugs&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;VI/B&lt;/strong&gt; - The use of antidepressant drugs, preferably selective serotonin reuptake inhibitors (SSRI), can be useful in the treatment of patients with dementia and depression. Trazodone can be useful in case of agitation.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Antipsychotic Drugs&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;II/A&lt;/strong&gt; - Antipsychotic drugs have partial efficacy in the treatment of psychosis and aggressiveness associated with dementia. Their use should be limited to at-risk, or extremely suffering patients or caregivers, and should be limited if possible in time, due to the potentially severe adverse effects of these drugs. Associations of antipsychotic drugs should be avoided.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Mood Stabilizers&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;V/A&lt;/strong&gt; - There is currently no evidence supporting the use of mood stabilizers for the treatment of behavioral disorders in patients with dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Benzodiazepines&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;V/A&lt;/strong&gt; - There is no evidence supporting the use of benzodiazepines in patients with dementia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Non-pharmacological Treatments (Behavioral)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;V/A&lt;/strong&gt; - The first line treatment for psychological and behavioral disorders is non-pharmacological, due to the potentially severe adverse effects caused by pharmacological treatments. The possibility of a non-pharmacological treatment for cognitive disorders should be considered at the diagnosis of dementia, even if evidence from the literature is not conclusive. Expected benefits should be discussed with patients and caregivers, and times and ways for the training and support of caregivers should be planned. General practitioners should refer to specialist services for these activities.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;I&lt;/strong&gt; Evidences from randomized controlled clinical trials and/or systematic reviews of randomized trials.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;II&lt;/strong&gt; Evidences from one single adequately designed randomized trial.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;III&lt;/strong&gt; Evidences from non-randomized cohort studies with concurrent or historical control or their metaanalysis.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;IV&lt;/strong&gt; Evidences from non-controlled retrospective case-control studies.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;V&lt;/strong&gt; Evidences from non-controlled case-series studies.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;VI&lt;/strong&gt; Evidences from experts' opinions or opinions from panels as indicated in guidelines or consensus conferences, or based on opinions from members of the work group responsible for this guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strength of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A &lt;/strong&gt;Carrying out the specified procedure or diagnostic test is strongly recommended. The recommendation is supported by good-quality evidences, even if not necessarily type I or II.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt; It would be inappropriate to always recommend the specified procedure or intervention, considered the still existing doubts, but it should anyway be carefully considered.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt; Significant uncertainties exist against recommending to carry out the specified procedure or intervention.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;D&lt;/strong&gt; The specified procedure is not recommended.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;E&lt;/strong&gt; The specified procedure is strongly not recommended.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Accurate diagnosis and appropriate treatment of dementia&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Acetylcholinesterase inhibitors&lt;/em&gt;: Adverse effects include cholinergic overstimulation. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Memantine&lt;/em&gt;: Reported adverse effects are instability, headache, stypsis, and sleepiness. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;There is a risk of increasing brain vascular accidents with &lt;em&gt;risperidone&lt;/em&gt; and &lt;em&gt;olanzapine&lt;/em&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Several data from the literature suggest that the use of &lt;em&gt;typical&lt;/em&gt; and &lt;em&gt;atypical antipsychotic drugs&lt;/em&gt; is associated with an increased risk of total mortality in older patients with dementia and with an increased risk of sudden cardiac death in the general population. These drugs are also associated with extrapyramidal side effects, such as parkinsonism, acute dystonia, acathisia, late dyskinesia, perioral tremor, and malignant neuroleptic syndrome. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Living with Illness" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Regional Health Council. Dementia. Diagnosis and treatment. Milan (Italy): Regione Toscana, Consiglio Sanitario Regionale; 2011. 38 p.  [131 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2011" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="Regione Toscana, Consiglio Sanitario Regionale - State/Local Government Agency [Non-U.S.]" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Regione Toscana, Consiglio Sanitario Regionale&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Regional Health Council&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Authors&lt;/em&gt;: Antonio Bavazzano (&lt;em&gt;Coordinator&lt;/em&gt;), Geriatrician, Coordinator of the Regional Center for the Coordination of the Network for the Assistance to Patients with Dementia; Carlo Adriano Biagini, Geriatrician, Regional President of the Italian Association of Psycho-geriatrics (AIP), Director UO of Geriatric, AUSL 3 Pistoia; Laura Bracco, Neurologist, 1&amp;deg; Neurological Clinic, University of Florence; Giovanni Carriero, General Practitioner, Siena; Maria Chiara Cavallini, Geriatrician, SOD Cardiology and Geriatric Medicine, DAI Hearth and Vessels, AOU Careggi; Andrea Fagiolini, Psychiatrist, Associate Professor of Psychiatry, University of Siena; Carlo Faravelli, Psychiatrist, Professor of Psychiatry, University of Florence; Antonio Federico, Professor of Neurology, University of Siena, Director of the UOC of Neurology and Neurometabolic Diseases, AOU Siena, President of the Italian Society of Neurology; Luciano Gabbani, Geriatrician, Director of the Geriatric Agency, AOU Careggi; Niccol&amp;ograve; Marchionni, Geriatrician, Professor of Geriatrics and Gerontology, University of Florence, National President of the Italian Society of Geriatrics and Gerontology (SIGG); Monica Marini, Nurse Direction, AUSL 3 Pistoia; Sandro Maurri, General Practitioner, Neurologist, Florence; Enrico Mossello, Geriatrician, Assistant Professor, University of Florence; Luigi Murri, Neurologist, Professor of Neurology, Director of the Faculty of Medicine and Surgery, University of Pisa; Alessio Nastruzzi, General Practitioner, Florence; Maristella Piccininni, Neurologist, UO of Neurology, Coordinator of Clinics for Cognitive Disorders, AUSL 10 Florence; Cristina Rossi, Director of the UO for Territorial Nursing Assistance, AUSL 10 Firenze; Gabriele Siciliano, Neurologist, Associate Professor of Neurology, Department of Neurosciences, Pisa AOU and University of Pisa; David Simoni, Psychologist, Coordinator of the Psychology of Aging Working Group, University of Florence and Tuscany Psychologists Association; Sandro Sorbi, Neurologist and Psychiatrist, Professor of Neurology, University of Florence; Paolo Stefani, General Practitioner, Pisa; Gloria Tognoni, Neurologist, UO of Neurology, AOU Pisa; Luigi Tonelli, Epidemiologist, Regional Health Council; Sandra Vannucci, Nurse Coordinator, AUSL 4 Prato&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;All the writers of this guideline, chosen for their expertise, have compiled a statement on possible conflicts of interest occurred in the job processing. Each has fully performed the work as part of their work for the Tuscan Health System (SST).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.regione.toscana.it/regione/export/RT/sito-RT/Contenuti/sezioni/salute/visualizza_asset.html_782917355.html&quot; title=&quot;Regione Toscana, Consiglio Sanitario Regionale Web site&quot;&gt;Regione Toscana, Consiglio Sanitario Regionale Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies available upon request from Mrs. Giuseppina Agata Stella, Regione Toscana, Consiglio Sanitario Regionale, via T. Alderotti 26/n, 50139 Firenze, Italy or e-mail to &lt;a href=&quot;mailto:csr@regione.toscana.it&quot;&gt;csr@regione.toscana.it&lt;/a&gt;. &lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on August 3, 2011. The information was verified by the guideline developer on September 5, 2011.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouseâ„¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
